search
Back to results

A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
MK1809
Comparator: Losartan
Comparator: Placebo
Sponsored by
Merck Sharp & Dohme LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Part 1:

  • Nonsmoker for at least 6 months
  • Body Mass Index (BMI) less than or equal to 29 kg/m2
  • In overall good health

Part 2:

  • Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2
  • In overall good health (patients with hypertension and/or hyperlipidemia are accepted)

Exclusion Criteria:

Part 1:

  • History of any cardiovascular disease or any clinically significant family history of cardiac arrhythmias or conduction abnormalities at an age less than 60 years
  • History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
  • History of cancer
  • Clinically significant history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
  • Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
  • History of asthma, severe wheezing, COPD, or other pulmonary disease
  • Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
  • Major surgery, donated blood or participated in another investigational drug(s) trial within 30 days
  • Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
  • Nitrate therapy within 4 weeks
  • History of significant drug allergy or history of food allergies

Part 2

  • History of any clinically significant cardiac or cardiovascular disease (other than hypertension)
  • History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder
  • History of cancer
  • History of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines)
  • Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety)
  • History of asthma, severe wheezing, COPD, or other pulmonary disease
  • Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties
  • Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years)
  • Surgery, significant blood loss, donated blood, or participated in another investigational drug(s) trial within 30 days
  • Nitrate therapy within 4 weeks
  • History of significant drug allergy

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm 3

    Arm 4

    Arm 5

    Arm 6

    Arm 7

    Arm 8

    Arm 9

    Arm 10

    Arm 11

    Arm 12

    Arm 13

    Arm 14

    Arm 15

    Arm Type

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Experimental

    Arm Label

    Part 1 A-1

    Part 1 A-2

    Part 1 A-3

    Part 1 A-4

    Part 1 A-5

    Part 1 B-1

    Part 1 B-2

    Part 1 B-3

    Part 1 B-4

    Part 1 B-5

    Part 2 C-1

    Part 2 C-2

    Part 2 C-3

    Part 2 C-4

    Part 2 C-5

    Arm Description

    Part 1; Panel A; Sequence 1: 2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan

    Part 1; Panel A; Sequence 2: Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809

    Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809

    Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo

    Part 1; Panel A; Sequence 5: Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809

    Part 1; Panel B; Sequence 1: 5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food

    Part 1; Panel B; Sequence 2: 5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food

    Part 1; Panel B; Sequence 3: 5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food

    Part 1; Panel B; Sequence 4: Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food

    Part 1; Panel B; Sequence 5: Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food

    Part 2; Panel C; Sequence 1: 50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan

    Part 2; Panel C; Sequence 2: 50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809

    Part 2; Panel C; Sequence 3: Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo

    Part 2; Panel C; Sequence 4: 50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809

    Part 2; Panel C; Sequence 5: Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809

    Outcomes

    Primary Outcome Measures

    Part I: Area under the plasma concentration (AUC) versus time curve in healthy adult male subjects in the fasted state
    Part 1: Trough plasma concentration in healthy adult male subjects in the fasted state
    Part 2: Safety and tolerability of rising single oral doses of MK1809 in adult hypertensive patients based on an assessment of clinical and laboratory adverse experiences

    Secondary Outcome Measures

    Part 1: Area under the plasma concentration (AUC) versus time curve resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
    Part 1: Maximum concentration of drug in the plasma (Cmax) resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
    Part 1: Number of clinical and laboratory adverse experiences (AEs) to assess safety and tolerability
    Part 2: Area under the plasma concentration (AUC) versus time curve of the E3174 metabolite
    Part 2: Trough plasma concentration of the E3174 metabolite

    Full Information

    First Posted
    December 15, 2009
    Last Updated
    September 25, 2018
    Sponsor
    Merck Sharp & Dohme LLC
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01033318
    Brief Title
    A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)
    Official Title
    A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2018
    Overall Recruitment Status
    Completed
    Study Start Date
    September 11, 2007 (Actual)
    Primary Completion Date
    June 19, 2008 (Actual)
    Study Completion Date
    June 19, 2008 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Merck Sharp & Dohme LLC

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The goal of this study is to identify at least one safe and well tolerated dose of MK1809 that has similar pharmacokinetic qualities as 100 mg losartan.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension
    Keywords
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    30 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Part 1 A-1
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel A; Sequence 1: 2 mg MK1809 / placebo / 50 mg MK1809 / 150 mg MK1809 / 100 mg Losartan
    Arm Title
    Part 1 A-2
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel A; Sequence 2: Losartan / 10 mg MK1809 / placebo / 150 mg MK1809 / 280 mg MK1809
    Arm Title
    Part 1 A-3
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel A; Sequence 3 2 mg MK1809 / 10 mg MK1809 / Losartan / Placebo / 280 mg MK1809
    Arm Title
    Part 1 A-4
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel A; Sequence 4 2 mg MK1809 / Losartan / 50 mg MK1809 / 150 mg MK1809 / Placebo
    Arm Title
    Part 1 A-5
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel A; Sequence 5: Placebo / 10 mg MK1809 / 50 mg MK1809 / Losartan / 280 mg MK1809
    Arm Title
    Part 1 B-1
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel B; Sequence 1: 5 mg MK1809 / Placebo / 100 mg MK1809 / 210 mg MK1809 / Placebo with food
    Arm Title
    Part 1 B-2
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel B; Sequence 2: 5 mg MK1809 / 25 mg MK1809/ Placebo / Losartan / 25 mg MK1809 with food
    Arm Title
    Part 1 B-3
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel B; Sequence 3: 5 mg MK1809 / Losartan / 100 mg MK1809 / 210 mg MK1809 / Losartan with food
    Arm Title
    Part 1 B-4
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel B; Sequence 4: Losartan / 25 mg MK1809/ 100 mg MK1809 / Placebo / 25 mg MK1809 with food
    Arm Title
    Part 1 B-5
    Arm Type
    Experimental
    Arm Description
    Part 1; Panel B; Sequence 5: Placebo / 25 mg MK1809/ Losartan / 210 mg MK1809 / 25 mg MK1809 with food
    Arm Title
    Part 2 C-1
    Arm Type
    Experimental
    Arm Description
    Part 2; Panel C; Sequence 1: 50 mg MK1809 / Placebo / 150 mg MK1809 / 210 mg MK1809 / Losartan
    Arm Title
    Part 2 C-2
    Arm Type
    Experimental
    Arm Description
    Part 2; Panel C; Sequence 2: 50 mg MK1809 / 100 mg MK1809/ Placebo / Losartan / 280 mg MK1809
    Arm Title
    Part 2 C-3
    Arm Type
    Experimental
    Arm Description
    Part 2; Panel C; Sequence 3: Losartan / 100 mg MK1809/ 150 mg MK1809 / 210 mg MK1809 / Placebo
    Arm Title
    Part 2 C-4
    Arm Type
    Experimental
    Arm Description
    Part 2; Panel C; Sequence 4: 50 mg MK1809 / Losartan / 150 mg MK1809 / Placebo / 280 mg MK1809
    Arm Title
    Part 2 C-5
    Arm Type
    Experimental
    Arm Description
    Part 2; Panel C; Sequence 5: Placebo / 100 mg MK1809/ Losartan / 210 mg MK1809 / 280 mg MK1809
    Intervention Type
    Drug
    Intervention Name(s)
    MK1809
    Intervention Description
    single oral doses of MK1809
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Losartan
    Other Intervention Name(s)
    Losartan
    Intervention Description
    single oral doses of 100 mg Losartan
    Intervention Type
    Drug
    Intervention Name(s)
    Comparator: Placebo
    Intervention Description
    Placebo to MK1809
    Primary Outcome Measure Information:
    Title
    Part I: Area under the plasma concentration (AUC) versus time curve in healthy adult male subjects in the fasted state
    Time Frame
    Through 32 hours postdose
    Title
    Part 1: Trough plasma concentration in healthy adult male subjects in the fasted state
    Time Frame
    24 hours postdose
    Title
    Part 2: Safety and tolerability of rising single oral doses of MK1809 in adult hypertensive patients based on an assessment of clinical and laboratory adverse experiences
    Time Frame
    Duration of study and up to 14 days after administration of the last dose of study drug
    Secondary Outcome Measure Information:
    Title
    Part 1: Area under the plasma concentration (AUC) versus time curve resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
    Time Frame
    24 hours postdose
    Title
    Part 1: Maximum concentration of drug in the plasma (Cmax) resulting from a single oral dose of MK1809 following a standard high-fat breakfast (compared to that observed with the identical dose level administered in the fasted state)
    Time Frame
    Through 32 hours postdose
    Title
    Part 1: Number of clinical and laboratory adverse experiences (AEs) to assess safety and tolerability
    Time Frame
    Duration of study and up to 14 days after administration of the last dose of study drug
    Title
    Part 2: Area under the plasma concentration (AUC) versus time curve of the E3174 metabolite
    Time Frame
    Through 32 hours postdose
    Title
    Part 2: Trough plasma concentration of the E3174 metabolite
    Time Frame
    Through 32 hours postdose

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Part 1: Nonsmoker for at least 6 months Body Mass Index (BMI) less than or equal to 29 kg/m2 In overall good health Part 2: Body Mass Index (BMI) greater than 18kg/m2 and less than or equal to 35kg/m2 In overall good health (patients with hypertension and/or hyperlipidemia are accepted) Exclusion Criteria: Part 1: History of any cardiovascular disease or any clinically significant family history of cardiac arrhythmias or conduction abnormalities at an age less than 60 years History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder History of cancer Clinically significant history of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines) Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety) History of asthma, severe wheezing, COPD, or other pulmonary disease Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties Major surgery, donated blood or participated in another investigational drug(s) trial within 30 days Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years) Nitrate therapy within 4 weeks History of significant drug allergy or history of food allergies Part 2 History of any clinically significant cardiac or cardiovascular disease (other than hypertension) History of any major endocrine, vascular, hematologic, gastrointestinal, hepatic, renal or genitourinary disease/disorder History of cancer History of a neurological disorder (includes epilepsy,stroke, transient ischemic attack, classic migraines) Active or history of a psychiatric disorder (includes depression, bipolar disorder, schizophrenia, anxiety) History of asthma, severe wheezing, COPD, or other pulmonary disease Individual or family history of bleeding or hemorrhagic diathesis, or bleeding difficulties Illicit drug use (including recreational); or history of drug or alcohol abuse (within 2 years) Surgery, significant blood loss, donated blood, or participated in another investigational drug(s) trial within 30 days Nitrate therapy within 4 weeks History of significant drug allergy
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Medical Monitor
    Organizational Affiliation
    Merck Sharp & Dohme LLC
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    A Study of the Pharmacokinetics and Pharmacodynamics of MK1809 (1809-001)(COMPLETED)

    We'll reach out to this number within 24 hrs